METHOD DEVELOPMENT AND VALIDATION FOR THE VILDAGLIPTIN BY RP-HPLC METHOD

Vijay Govindrao Napate*1 and Pratik Anantrao Napate2

1*Department of Quality Assurance, Dr. Vedprakash Patil Pharmacy College, Aurangabad, Maharashtra, India.
2Department of Statistic, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India.

ABSTRACT
A new simple, specific, precise and accurate RP-HPLC method has been for determination of vildagliptin in pharmaceutical dosage form. An Altima C18 column (150mm x 4.6mm, 5μm) as stationary phase. A mixture of dilute phosphoric acid solution pH 2.6±0.5 as buffer and acetonitrile in the ratio of 40:60 v/v was prepared and it is used as mobile phase. Injection volume was 10μL and flow rate was 0.5mL/min and run time was 6.0min. The column was maintained at ambient temperature and the eluent was monitored at 210nm. The retention time for vildagliptin was 3.05. The correlation coefficient value of Vildagliptin was 0.999. The validation method was developed as per ICH guidelines. The developed technique was validated for accuracy, precision, linearity, robustness, system suitability, specificity studies and result was analyzed according to the ICH guideline.

KEYWORDS
RP-HPLC method, Vildagliptin, Phosphoric acid, Acetonitrile and ICH guidelines.

INTRODUCTION
Vildagliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor and used as oral potential anti-diabetic agent for treatment of type 2 diabetes mellitus1. IUPAC name of Vildagliptin is (1-[(3-Hydroxy-adamant-1-ylamino) acetyl]- pyrrolidine-2 (S)- carbonitrile2 and is having molecular weight 303.4023. Pharmacologically, it acts as selective DPP-4 inhibitor. European Medicines Agency issued approval for use of vildagliptin in the European Union in February 2008 and is also listed on Australian Pharmaceutical Benefits Scheme1.
Literature survey revealed that few analytical methods such as spectrophotometric, HPLC and LC-MS methods have been reported for the estimation of Vildagliptin in combination with other drug or in alone. Hence a new accurate, sensitive and less time consuming HPLC method was developed and validated as per ICH guidelines for the estimation of Vildagliptin in bulk sample and in pharmaceutical dosage form.

**MATERIAL AND METHODS**

**Chemicals and Reagents**

Pharmaceutical grade Vildagliptin, gifted from Harman Finochem, Aurangabad. Galvus tablets nominally containing 50mg Vildagliptin per tablet purchased from local market. HPLC grade Acetonitrile, phosphoric acid and water procure from Shodh Advantech, Aurangabad.

**Instrumentation**

The liquid chromatographic system consisted of Waters HPLC system equipped with a reverse phase Altima C18 column (150mm x 4.6mm; 5μm), a 10μL injection loop, UV 1000 detector, running on Chrom Quest Software. Electronic balance was used for weighing purpose.

**Chromatographic conditions**

HPLC was connected with Altima C18 column (150mm x 4.6mm, 5μm) as stationary phase. A mixture of dilute phosphoric acid solution pH 2.6±0.5 as buffer and acetonitrile in the ratio of 40:60 v/v was prepared and it is used as mobile phase. The phosphoric acid buffer solution was prepared by transferring about 1ml of concentrated phosphoric acid into 1000ml standard flask, add 400ml of milli-Q water, mix and dilute to volume with milli-Q water, sonication was done for five minutes and cool to room temperature, pH of above solution was measure and adjusted the pH to 2.6 with phosphoric acid solution and filtered through 0.45μ nylon filter. Injection volume was 10μL and flow rate was 0.5mL/min and run time was 6.0 min. The column was kept at ambient temperature and the eluent was monitored at 210nm.

**Preparation of standard stock solution**

5.0mg of Vildagliptin powder dissolve in 50ml of mobile phase. For complete dissolution of drug sonication method was used. Then, pipette out 10ml of above stock solution into 100ml mobile phase to become 10μg/ml solution.

**Preparation of sample solution**

10 tablets were weighed and finely powdered. An accurately weighed portion of powder sample equivalent to 5mg of Vildagliptin was transferred to volumetric flask and is dissolved in 50ml of the mobile phase. For complete dissolution of drug sonication method was used. Then filtered it. Then, pipette out 10ml of above stock solution into 100ml mobile phase to become 10μg/ml solution.

**Calibration curve**

Appropriate dilutions of standard Vildagliptin stock solution were taken in different volumetric flasks and resultant solution was diluted up to the mark with mobile phase to obtain final volumetric flasks. These solutions were injected into chromatographic system injector, peak area ratio was determined for each concentration of drug solution with the help of obtained chromatogram. Linearity curve of Vildagliptin was constructed by plotting peak area ratio versus applied concentration of Vildagliptin and linear regression model can be fitted. Similarly, the sample solution was chromatographed and concentration of Vildagliptin in tablet sample was found out using linear regression model.

**METHOD VALIDATION**

The validation method was developed as per ICH guidelines and accordingly the parameter evaluated were accuracy, precision, linearity, robustness, system suitability, specificity studies. For all parameters %RSD were calculated.

**Accuracy: (Recovery studies)**

The accuracy of the method was determined by calculating recovery of Vildagliptin by the method of standard addition. Recovery studies were performed by application of method to pre-analyzed sample by adding known amount of vildagliptin which corresponds to 50, 100 and 150 % label claim. From the above analysis, percentage recovery and standard deviation of percentage recovery were calculated.

Available online: www.uptodateresearchpublication.com
Precision
The precision of an analytical procedure describes the closeness of agreement between series of measurements obtained from multiple sampling of same homogeneous sample under the prescribed conditions.

Intra-day precision
It was determined by analyzing vildagliptin standard solutions at three different concentrations in linearity range for thrice on the same day. Each concentration was spotted in triplicate and % R.S.D. was determined.

Inter-day precision
Standard drug solutions at three different concentrations on different three days over a period of one week were analyzed and % R.S.D. was calculated.

Linearity
The linearity of an analytical is its ability to obtain test result, which are directly proportional to the concentration of analyte in the sample. Calibration curves is used to determine the linearity. For HPLC methods, the linear relationship between detector response and analyte concentration is determined. The linearity of the method was determined at six concentration levels ranging from 5 to 30ppm for Vildagliptin. Evaluation of the drug was performed with UV detector at 210nm, peak area was recorded for all the peaks. The correlation coefficient value of Vildagliptin was 0.99987.

Robustness
The robustness of an analytical procedure is measure of its capacity to remain unaffected by small, but deliberate variation in method parameters. It provide an information of its reliability during normal usage. The robustness of the method was evaluated, during method development by analyzing the effects of small variation in the change in wavelength (±1nm) and change in flow rate (±0.1ml /min).

System suitability
System suitability study of the method was carried out by six replicate analysis of solution containing 100% target concentration of Vildagliptin. Various chromatographic parameters such as retention time, peak area, tailing factor, USP therotical plate, asymmetry factor and resolution between the peaks were determined and the method was evaluated by analyzing these parameters.

Specificity
Specificity is the ability of method to measure the analyte in the presence of other relevant components those are expected to be present in sample. To determine the specificity of the method, standard sample of Vildagliptin were injected first. Then marketed product, blank and excipients solution were run in the instrument one after another.

Limit of detection and Limit of quantification
The limit of detection of an individual analytical procedure is the lowest amount of analyte in a sample which can be find out but not necessarily described as an exact value. The limit of quantification of an individual analytical procedure is the lowest amount of analyte in sample which can be quantitatively determined.
LOD and LOQ were calculated by using ICH guidelines.
LOD = 3.3 × SD/SLOPE
LOQ = 10 × SD/SLOPE
And SD (Standard Deviation) is calculated by using R Studio software and MS -Excel.

RESULTS AND DISCUSSION
The procedure was reform with a view to develop an accurate, specific and precise HPLC method in tablet dosage form using Altima C18 column (150mm x 4.6mm, 5μm). The use of dilute phosphoric acid and acetonitrile as a mobile phase in the ratio of 40:60 v/v resulted in peak with good shape and resolution. The flow rate was 0.5ml/min and the drug component was measured with UV detector at 210nm.

Results of system suitability are summarized in Table No.2. Six consecutive injections of the standard solution showed uniform retention time, plate USP count, tailing facto, linearity range, slope for both the drugs which indicate a good system for analysis.

Chromatograms shown in Figure No.2 and Figure No.3 explain that retention time for standard sample and commercial product of Vildagliptin are same.
This proves that, analytical method was not affected by excipients and also blank peak did not overlap drug peak. So the method is highly selective. A linear relationship between peak areas versus concentrations was observed for Vildagliptin in the range of 5% to 30% of nominal concentration. The correlation coefficient is 0.999 which shows that method is linear. Linearity curve of Vildagliptin is shown in Figure No.4.

Results of Intra-day and inter-day variability were summarized in Table No.4. The % RSD of peak areas was calculated for various trial. The method is highly precise as % RSD of peak area was less than 1% in all tests.

Results of recovery study are presented in Table No.5. The measured value was obtained by recovery test. Peaked amount of both the drug were compared against the recovery amount. % Recovery was 98.97% for Vildagliptin.

The results of robustness of the present method showed that small changes were made in the flow rate and wavelength did not produce significant changes in analytical results which determines that the method is robust. All the results describes that the method is accurate.

### Table No.1: Optimized chromatographic conditions of Vildagliptin

| S.No | Parameter                | Condition                                           |
|------|--------------------------|-----------------------------------------------------|
| 1    | Mobile phase             | 0.1 % phosphoric acid : Acetonitrile (40:60)        |
| 2    | pH                       | 2.6                                                 |
| 3    | Diluent                  | Water                                               |
| 4    | Column                   | Altima C18 column (150mm x 4.6mm, 5μm)              |
| 5    | Column temperature       | Ambient                                             |
| 6    | Wavelength               | 210nm                                               |
| 7    | Injection volume         | 10μl                                                |
| 8    | Flow rate                | 0.5ml/min                                           |
| 9    | Retention time           | 3.05                                                |
| 10   | Run time                 | 6 min                                               |

### Table No.2: Result of system suitability tests of Vildagliptin

| S.No | Parameter                  | Range     |
|------|----------------------------|-----------|
| 1    | Linearity range (μg/ml)    | 5-30      |
| 2    | Slope                      | 16409     |
| 3    | Intercept                  | 18037     |
| 4    | Retention time             | 3.05      |
| 5    | Correlation coefficient    | 0.999     |
| 6    | Theoretical plates (N)     | 5892      |
| 7    | Tailing factor             | 1.42      |
| 8    | LOD (μg/ml)                | 1.36      |
| 9    | LOQ (μg/ml)                | 4.12      |

### Table No.3: Linearity results of Vildagliptin

| S.No | Concentration | Area   |
|------|---------------|--------|
| 1    | 5             | 97097  |
| 2    | 10            | 183194 |
| 3    | 15            | 265653 |
| 4    | 20            | 348775 |
| 5    | 25            | 429412 |
| 6    | 30            | 507067 |
Table No.4: Intra-day and inter-day precision result of Vildagliptin

| S.No | Concentration (μg/ml) | Intra-day precision (%RSD) | Inter-day precision (%RSD) |
|------|-----------------------|-----------------------------|-----------------------------|
| 1    | 7 (μg/ml)             | 0.53                        | 0.79                        |

Table No.5: Recovery results of Vildagliptin

| S.No | Level   | Standard concentration (μg/ml) | Concentration added (μg/ml) | Concentration found (μg/ml) | % Recovery | Mean recovery |
|------|---------|--------------------------------|----------------------------|----------------------------|------------|---------------|
| 1    | 50%     | 10                             | 5                          | 14.91                      | 99.40      |               |
| 2    | 100%    | 10                             | 10                         | 19.6                       | 98         |               |
| 3    | 150%    | 10                             | 15                         | 24.88                      | 99.52      |               |

Table No.6: Assay results of Vildagliptin

| S.No | Formulation | Label claim | Amount found | % Assay |
|------|-------------|-------------|--------------|---------|
| 1    | Galvus      | 50mg        | 49.96        | 99.92   |

Table No.7: Results for robustness test of Vildagliptin

| S.No | Parameter         | Flow change | Wavelength Change |
|------|-------------------|-------------|-------------------|
| 1    | Condition         | 0.4         | 0.6               | 209nm   | 211nm   |
| 2    | Area              | 174323      | 162004            | 160083  | 161796  |
| 3    | Retention time    | 3.60        | 2.70              | 3.08    | 3.08    |

Figure No.1: Structure of Vildagliptin
Figure No.2: Typical Chromatogram of standard Vildaglaptin

Figure No.3: Typical chromatogram of Vildaglaptin in marketed formulation
CONCLUSION
The proposed RP-HPLC has been validated as per the ICH guidelines. The method was found to be very simple, sensitive, accurate and precise. Percentage of recovery shows that the method is free from interference of the excipients used in the formulation and shows acceptable correlation coefficient. The advantages of proposed method are short analysis time and a simple procedure for sample preparation. Therefore, the above method can be used for analysis of estimation of Vildagliptin in its tablet dosage form.

ACKNOWLEDGEMENT
I am very thankful to Department of Quality Assurance, faculty of Dr. Vedprakash Patil Pharmacy College, Aurangabad. I would also like to thank the Management of College, for providing the necessary facilities to carry out this work.

CONFLICT OF INTEREST
We declare that we have no conflict of interest.

BIBLIOGRAPHY
1. Vildagliptin. Wikipedia, http://en.Wikipedia.org/wiki/vildagliptin, 2020.
2. Indian Pharmacopoeia, The controller of publication, New Delhi, 1, 4th Edition, 1996.
3. United states pharmacopoeia, USP 30, NF 25, Rockville, MD, 2007.
4. Abu Dayyih W, Hamad M, Mallah E, Abu Dayyih A, Awad R, Zakaria Z, Arafat T. Method development and validation of vildagliptin and metformin HCL in pharmaceutical dosage form by reverse phase-high performance liquid chromatography, International Journal of Pharmaceutical Sciences and Research, 9(7), 2018, 2965-2972.
5. Hanumantha Rao K, Lakshmana Rao A, Chadrasekhar K. Development and validation of HPLC method for the estimation of vildagliptin in pharmaceutical dosage form, International Journal of Pharmaceutical, Chemical and Biological Sciences, 4(2), 2014, 361-366.
6. ICH Harmonised Tripartite Guideline. Validation of analytical procedures: Text and Methodology, Q2(R1), USA, 2005, 1-13.
7. ICH Harmonised Tripartite Guideline, Q2b, 1996.
8. ICH Harmonised Tripartite Guideline, Q2A, 1994.
9. Shrikrishna B B, Sugandha V M, Nisharani S R. Development and validation of RP-HPLC method for simultaneous estimation of vildagliptin and metformin, Research Journal
of Pharmaceutical Dosage Forms and Technology, 5(2), 2013, 95-98.

10. Aparajita M, Bishwajit B, Dilriba N. Development and validation of RP-HPLC method for estimation of vildagliptin from tablet dosage form, International Journal of Pharmaceutical and Life Sciences, 1(1), 2012, 1-8.

11. Gurdeep R Chatwal and Sham K Anand. Instrumental method of chemical analysis, Himalaya Publishing House, 5th Edition, 2010, 2.624-2.631.

12. Santosha B, Ravindranath A, Sundari C. Validated method for the simultaneous estimation of metformin hydrochloride and vildagliptin by RP-HPLC in bulk and the pharmaceutical dosage form, International Research Journal of Pharmaceutical And Applied Sciences, 2(3), 2012, 22-28.

13. Pragati R S, Mohan G, Sharma S. Development and validation of RP-HPLC for assay of vildagliptin, World Journal of Pharmacy Pharmaceutical Sciences, 3(2), 2014, 2303-2310.

14. Rahim K, Mira Zunnabai Md. A validated reverse phase HPLC method for the determination of vildagliptin from tablet dosage form, International Journal of Pharmaceutical and Life Sciences, 2(3), 2013, 2305-0330.

15. Ramkrishna J R, Dabhade M P, Shekhar V K, Vikas S S, Wasim Chand S. RP-HPLC method development and validation of vildagliptin in bulk and dosage form, World Journal of Pharmacy and Pharmaceutical Sciences, 6(9), 2017, 1161-1176.

16. Ramesh J, Senthil Kumar N. Stability indicating RP-HPLC method development and validation for the simultaneous determination of vildagliptin and metformin in pharmaceutical dosage form, International Journal of Pharmacy and Pharmaceutical Sciences, 9(3), 2017, 0975-1491.